Loading
A phase 3 trial of Pomalidomide, Dexamethasone, Venetoclax in multiple myeloma, run by AbbVie, active and no longer recruiting.
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. is a phase 3 interventional study registered as NCT03539744 by AbbVie, with 265 participants enrolled, started 2018-10-22 and due to reach its primary completion in 2026-08. Interventions recorded: Pomalidomide, Dexamethasone, Venetoclax. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares BCL-2 inhibitors, Relapsed or refractory multiple myeloma, Venetoclax, Multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/